Diretrizes sobre trombose venosa profunda da Sociedade Brasileira de Angiologia e Cirurgia Vascular
Guidelines on deep vein thrombosis of the Brazilian Society of Angiology and Vascular Surgery
Marcone Lima Sobreira; Marcos Áreas Marques; Adilson Ferraz Paschoa; Alcides José Araújo Ribeiro; Ivan Benaduce Casella; Marcelo Calil Burihan; Marcelo Fernando Matielo; Rafael de Athayde Soares; Walter Junior Boin de Araujo; Edwaldo Edner Joviliano; Julio Cesar Peclat de Oliveira
Resumo
Palavras-chave
Abstract
Deep vein thrombosis is one of the main causes of inpatient and outpatient morbidity, both in medical and surgical patients, significantly impacting mortality statistics and requiring prompt diagnosis so that treatment can be initiated immediately. This document was prepared and reviewed by 11 specialists certified by the Brazilian Society of Angiology and Vascular Surgery, who searched the main databases for the best evidence on the diagnostic (physical examination, imaging) and therapeutic approaches (heparin, coumarins, direct oral anticoagulants, fibrinolytics) to the disease.
Keywords
Referências
1 Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2, Suppl):e351S-418S.
2 Barros MVL, Pereira VSR, Pinto DM. Controvérsias no diagnóstico e tratamento da trombose venosa profunda pela ecografia vascular controversies in the diagnosis and treatment of deep vein thrombosis for vascular ultrasound. J Vasc Bras. 2012;11(2):137-43.
3 McManus RJ, Fitzmaurice DA, Murray E, Taylor C. Thromboembolism. Clin. Evid. 2010;2011:1-23.
4 Lopes LC, Eikelboom J, Spencer FA, et al. Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis. BMJ Open. 2014;4(7):e005674.
5 Gabriel F, Portolés O, Labiós M, et al. Usefulness of thrombophilia testing in venous thromboembolic disease: findings from the RIETE registry. Clin Appl Thromb Hemost. 2013;19(1):42-7.
6 Veiga AGM, Passeri CR, Papini SJ. Tromboembolismo venoso. Rev Bras Med. 2014;(1):1-6.
7 Giannini M, Rollo HA, Maffei FHA. O papel do mapeamento dúplex no diagnóstico da trombose venosa profunda assintomática dos membros inferiores. J Vasc Bras. 2005;4(3):290-6.
8 Geersing GJ, Zuithoff NPA, Kearon C, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups : individual patient data meta-analysis. BMJ. 2014;348(3):g1340.
9 Segal JB, Eng J, Tamariz LJ, Bass EB. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med. 2007;5(1):63-73.
10 Wells P, Owen C, Doucette S, Fergusson D, Tran H. Does this patient have deep vein thrombosis? JAMA. 2006;295(2):199-207.
11 Izcovich A, Cuker A, Kunkle R, et al. A user guide to the American Society of Hematology clinical practice guidelines. Blood Adv. 2020;4(9):2095-110.
12 Wells P, Hirsh J, Anderson D, et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet. 1995;345(8961):1326-30.
13 National Clinical Guideline Centre (UK). Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing [Internet]. London: Royal College of Physicians; 2012 [citado 2017 jul 28].
14 Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. J Am Coll Cardiol. 2017;70(19):2411-20.
15 Adams D, Welch JL, Kline JA. Clinical utility of an age-adjusted D-dimer in the diagnosis of venous thromboembolism. Ann Emerg Med. 2014;64(3):232-4.
16 Kovac M, Mikovic Z, Rakicevic L, et al. The use of D-dimer with new cutoff can be useful in diagnosis of venous thromboembolism in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2010;148(1):27-30.
17 Cohen AT, Spiro TE, Spyropoulos AC, et al. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost. 2014;12(4):479-87.
18 Cushman M, Folsom AR, Wang L, et al. Fibrin fragment d-dimer and the risk of future venous thrombosis. Blood. 2003;101(4):1243-8.
19 Arpaia G, Carpenedo M, Verga M, et al. d-Dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis. 2009;20(3):170-5.
20 Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27(25):4124-9.
21 Kodama J, Seki N, Masahiro S, et al. d-Dimer level as a risk factor for postoperative venous thromboembolism in Japanese women with gynecologic cancer. Ann Oncol. 2010;21(8):1651-6.
22 Verhovsek M, Douketis JD, Yi Q, et al. Systematic review: d-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008;149(7):481-90, W94.
23 Douketis J, Tosetto A, Marcucci M, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of d-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010;153(8):523-31.
24 Steinbrecher O, Šinkovec H, Eischer L, Kyrle PA, Eichinger S. D-dimer levels over time after anticoagulation and the association with recurrent venous thromboembolism. Thromb Res. 2021;197:160-4.
25 Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):1612-20.
26 Marchandot B, Sattler L, Jesel L, et al. COVID-19 related coagulopathy: a distinct entity? J Clin Med. 2020;9(6):1651.
27 Zhao R, Su Z, Komissarov AA, et al. Associations of D-dimer on admission and clinical features of COVID-19 patients: a systematic review, meta-analysis, and meta-regression. Front Immunol. 2021;12:691249.
28 Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2021;26(3):107-8.
29 Zhang L, Yan X, Fan Q, et al. D-Dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324-9.
30 Athayde Soares R, Matielo MF, Brochado FC No, Nogueira MP, Almeida RD, Sacilotto R. Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery. 2019;166(6):1076-83.
31 Roberts LN, Patel RK, Goss DE, Chitongo P, Bonner L, Arya R. Relationship between development of post-thrombotic syndrome and serial ultrasound, D-dimer, and factor VIII activity after a first deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2016;4(1):28-35.
32 Qaseem A, Snow V, Barry P, et al. Current diagnosis of venous thrombo- embolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the. Ann Fam Med. 2007;5(1):57-62.
33 Mustafa BO, Rathbun SW, Whitsett TL, Raskob GE. Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review. Arch Intern Med. 2002;162(4):401-4.
34 Pomero F, Borretta V, Bonzini M, et al. Accuracy of emergency physician-performed ultrasonography in the diagnosis of deep-vein thrombosis: a systematic review and meta-analysis. Thromb Haemost. 2013;109(1):137-45.
35 Gaitini D. Current approaches and controversial issues in the diagnosis of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound. 2006;34(6):289-97.
36 Huisman M, Klok F. Diagnostic management of acute deep vein thrombosis and pulmonary embolism. J Thromb Haemost. 2013;11(3):412-22.
37 Di Nisio M, Squizzato A, Rutjes AW, Büller HR, Zwinderman AH, Bossuyt PM. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost. 2007;5(2):296-304.
38 Sidawy AP, Perler BA. Rutherford’s vascular surgery and endovascular therapy. 2- volume set. Philadelphia: Elsevier; 2022.
39 Needleman L, Cronan JJ, Lilly MP, et al. Ultrasound for lower extremity deep venous thrombosis: multidisciplinary recommendations from the Society of Radiologists in Ultrasound Consensus Conference. Circulation. 2018;137(14):1505-15.
40 Aurshina A, Ascher E, Hingorani A, Salles-Cunha SX, Marks N, Iadgarova E. Clinical role of the “venous” ultrasound to identify lower extremity pathology. Ann Vasc Surg. 2017;38:274-8.
41 Ozbudak O, Erogullari I, Ogus C, Cilli A, Türkay M, Ozdemir T. Doppler ultrasonography versus venography in the detection of deep vein thrombosis in patients with pulmonary embolism. J Thromb Thrombolysis. 2006;21(2):159-62.
42 Thomas SM, Goodacre SW, Sampson FC, van Beek EJR. Diagnostic value of CT for deep vein thrombosis : results of a systematic review and meta-analysis. Clin Radiol. 2008;63(3):299-304.
43 Sharma P, Kumar R, Jeph S, et al. 18F-FDG PET-CT in the diagnosis of tumor thrombus: can it be differentiated from benign thrombus? Nucl Med Commun. 2011;32(9):782-8.
44 Peterson DA, Kazerooni EA, Wakefield TW, et al. Computed tomo- graphic venography is specific but not sensitive for diagnosis of acute lower-extremity deep venous thrombosis in patients with suspected pulmonary embolus. J Vasc Surg. 2001;34(5):798-804.
45 Sampson FC, Goodacre SW, Thomas SM, van Beek EJR. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol. 2007;17(1):175-81.
46 Bernardi E, Camporese G, Büller HR, et al. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. JAMA. 2008;300(14):1653-9.
47 Sidawy AP, Perler BA. Rutherford’s vascular surgery and endovascular therapy. 2- volume set. Philadelphia: Elsevier; 2022. 1960 p.
48 Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016;41(1):32-67.
49 Kahn SR. The post-thrombotic syndrome. Hematology. 2016;2016(1):413-8.
50 Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med. 2017;377(23):2240-52.
51 Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2, Suppl):e419S-96S.
52 Kruger PC, Eikelboom JW, Douketis JD, Hankey GJ. Deep vein thrombosis: update on diagnosis and management. Med J Aust. 2019;210(11):516-24.
53 Othieno R, Abu Affan M, Okpo E. Prevention and treatment of venous thromboembolism: international consensus statement (guidelines according to scientific evidence). Clin Appl Thromb Hemost. 2013;19(2):116-8.
54 Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6, Suppl):454S-545S.
55 Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban – metabolism, pharmacologic properties and drug interactions. Curr Drug Metab. 2017;18(7):636-42. PMid:28524005.
56 Santos FCJC, Alves JL Jr, Gavilanes F, et al. New anticoagulants for the treatment of venous thromboembolism. J Bras Pneumol. 2016;42(2):146-54.
57 Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban: metabolism, pharmacologic properties and drug interactions. Curr Drug Metab. 2017;18(7):636-42. PMid:28524005.
58 Thomas TF, Ganetsky V, Spinler SA. Rivaroxaban: an oral factor Xa inhibitor. Clin Ther. 2013;35(1):4-27.
59 Farge D, Frere C, Connors JM, et al. Diretrizes internacionais de prática clínica de 2019 para o tratamento e profilaxia de doenças venosas tromboembolismo em pacientes com câncer. Lancet Oncol. 2019;20(10):e566.
60 Yoshida WB. Anticoagulantes orais diretos no tratamento do tromboembolismo venoso em pacientes com câncer. J Vasc Bras. 2016;15(4):263-4.
61 Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510.
62 Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97.
63 Daiichi Sankyo Europe GmbH. First market approval in Japan for LIXIANA (Edoxaban). Tokyo; 2011. Press release. Archived from the original on 2013 Nov 2006.
64 O’Riordan M. FDA approves edoxaban for stroke prevention in AF and DVT/PE prevention. New York: Medscape, Inc.; 2015.
65 Parasrampuria DA, Kanamaru T, Connor A, et al. Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule. J Clin Pharmacol. 2015;55(11):1286-92.
66 U.S. Food and Drug Administration. Savaysa (edoxaban) tablets [Internet]. 2019 [citado 2019 set 18].
67 Mendell J, Tachibana M, Shi M, Kunitada S. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol. 2011;51(5):687-94.
68 Martin KA, Lee CR, Farrell TM, Moll S. Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance. Am J Med. 2017;130(5):517-24.
69 Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6(9):1542-9.
70 Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743-53.
71 Vanassche T, Verhamme P, Wells PS, et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edox- aban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res. 2018;162:7-14.
72 Takahashi N, Mukai Y, Kimura T, et al. Efficacy and safety of uninterrupted periprocedural edoxaban in patients undergoing catheter ablation for atrial fibrillation: the prospective KYU-RABLE study. Circ J. 2019;83(10):2017-24.
73 Nakamura M, Yamada N, Asamura T, Shiosakai K, Uchino K. Safety and effectiveness of edoxaban in Japanese patients with venous thromboembolism: an interim analysis of data from a Japanese postmarketing observational study (ETNA-VTE-Japan). Circ J. 2019;83(6):1394-404.
74 Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-15.
75 Radulescu VC. Anticoagulation therapy in children. Semin Thromb Hemost. 2017;43(8):877-85.
76 Goldenberg NA, Takemoto CM, Yee DL, Kittelson JM, Massicotte MP. Improving evidence on anticoagulant therapies for venous thromboembolism in children: key challenges and opportunities. Blood. 2015;126(24):2541-7.
77 Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-15.
78 Ikeda S, Koga S, Yamagata Y, et al. Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous throm- boembolism between patients with and without cancer. J Cardiol. 2018;72(2):120-7.
79 Hara N, Miyamoto T, Iwai T, et al. Assessment of the safety and efficacy of edoxaban for the treatment of venous thromboembolism secondary to active malignancy. Ann Vasc Dis. 2017;10(4):407-10.
80 Hur M, Park SK, Koo CH, et al. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty. Acta Orthop. 2017;88(6):634-41.
81 Venker BT, Ganti BR, Lin H, Lee ED, Nunley RM, Gage BF. safety and efficacy of new anticoagulants for the prevention of venous thromboembolism after hip and knee arthroplasty: a meta-analysis. J Arthroplasty. 2017;32(2):645-52.
82 Kawai Y, Fuji T, Fujita S, et al. Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials. Thromb J. 2016;14(1):48.
83 Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. J Thromb Haemost. 2008;6(8):1313-8.
84 You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9. ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2, Suppl):e531S-75S.
85 Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2, Suppl):e278S-325S.
86 Frost C. Assessment of the sites of gastrointestinal absorption of apixaban in healthy subjects. Clin Pharmacol Drug Dev. 2013;2(Suppl 1):19.
87 U.S. Food and Drug Administration. Eliquis (apixaban) tablets [Internet]. 2019 [citado 2019 set 18].
88 He K, Luettgen JM, Zhang D, et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet. 2011;36(3):129-39.
89 Al Mukdad M, Al-Badriyeh D, Elewa HF. Cost-effectiveness evaluations among the direct oral anticoagulants for the prevention and treatment of venous thromboembolism: systematic review. Clin Appl Thromb Hemost. 2019;25:1076029619849103.
90 Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385-413.
91 Prom R, Spinler SA. The role of apixaban for venous and arterial thromboembolic disease. Ann Pharmacother. 2011;45(10):1262-83.
92 Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808.
93 Cushman M. Treating acute venous thromboembolism: shift with care. N Engl J Med. 2013;369(9):865-6.
94 Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708.
95 Connors JM. Extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):767-9.
96 Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92.
97 Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other thromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331-9.
98 Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178-85.
99 Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38(3):448-58.
100 Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52.
101 Boehringer Ingelheim. Pradaxa [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2023.
102 Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-72.
103 Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170(19):1710-6.
104 Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199-205.
105 Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997;336(6):393-8.
106 Prins MH, Lensing AWA, Prandoni P, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv. 2018;2(7):788-96.
107 Couturaud F, Sanchez O, Pernod G, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial. JAMA. 2015;314(1):31-40.
108 Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low- intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348(15):1425-34.
109 Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709-18.
110 Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510.
111 Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211-22.
112 Agnelli G, Hoffmann U, Hainaut P, et al. ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. Thromb Res. 2020;196:297-304.
113 Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med. 1998;104(4):332-8.
114 Alhousani M, Malik SU, Abu-Hashyeh A, et al. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2021;198:103-14.
115 Chindamo MC, Marques MA. Avaliação do risco de sangramento na profilaxia do tromboembolismo venoso. J Vasc Bras. 2021;20:e20200109.
116 Kakkos SK, Gohel M, Baekgaard N, et al. European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg. 2021;61(1):9-82.
117 Starr JA, Pinner NA, Mannis M, Stuart MK. A review of direct oral anticoagulants in patients with stage 5 or end-stage kidney disease. Ann Pharmacother. 2022;56(6):691-703.
118 Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257-91.
119 Wang X, Ma Y, Hui X, et al. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis. Cochrane Database Syst Rev. 2023;4(4):CD010956.
120 Oliveira ALML, Marques MA. Profilaxia de tromboembolismo venoso na gestação. J Vasc Bras. 2016;15(4):293-301.
121 Federação Brasileira das Associações de Ginecologia e Obstetrícia. Tromboembolismo venoso na gestação: protocolos FEBRASGO. São Paulo: Comissão Nacional Especializada em Tromboembolismo Venoso; 2018. (Protocolo FEBRASGO-Obstetrícia; no. 56).
122 Basu S, Aggarwal P, Kakani N, Kumar A. Low-dose maternal warfarin intake resulting in fetal warfarin syndrome: In search for a safe anticoagulant regimen during pregnancy. Birth Defects Res A Clin Mol Teratol. 2016;106(2):142-7.
123 Oliveira ALML, Paschôa AF, Marques MA. Tromboembolismo venoso na mulher: novos desafios para uma velha doença. J Vasc Bras. 2020;19:e20190148.
124 Federação Brasileira das Associações de Ginecologia e Obstetrícia. Prevenção do tromboembolismo na gestante hospitalizada e no puerpério. São Paulo: Comissão Nacional Especializada em Tromboembolismo Venoso; 2021. (Protocolo FEBRASGO-Obstetrícia; no. 58).
125 Marques MA, Teruchkin MM, Oliveira ALML. Venous thromboembolism in transgender women. J Vasc Bras. 2023;21:e20220120.
126 Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011;342(2):d3036.
127 Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003;139(1):19-25.
128 Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603.
129 Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367(21):1979-87.
130 Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366(21):1959-67.
131 Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708.
132 Schulman S, Singer D, Ageno W, Casella IB, Desch M, Goldhaber SZ. NOACs for treatment of venous thromboembolism in clinical practice. Thromb Haemost. 2017;117(7):1317-25.
133 Goldhaber SZ, Ageno W, Casella IB, et al. Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. J Thromb Thrombolysis. 2022;53(2):399-409.
134 Schellong S, Ageno W, Casella IB, et al. Profile of patients with isolated distal deep vein thrombosis versus proximal deep vein thrombosis or pulmonary embolism: RE-COVERY DVT/PE study. Semin Thromb Hemost. 2022;48(4):446-58.
135 Ageno W, Casella IB, Chee KH, et al. Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. J Thromb Thrombolysis. 2021;51(3):561-70.
136 Ageno W, Mantovani LG, Haas S, et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol. 2016;3(1):e12-21.
137 Beyer-Westendorf J, Gelbricht V, Forster K, et al. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry. Br J Clin Pharmacol. 2014;78(4):908-17.
138 Beyer-Westendorf J, Forster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955-62.
139 Kucher N, Aujesky D, Beer JH, et al. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER). Thromb Haemost. 2016;116(3):472-9. PMid:27346301.
140 Turpie AGG, Farjat AE, Haas S, et al. 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE. Thromb Res. 2023;222:31-9.
141 Ageno W, Haas S, Weitz JI, et al. Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE registry. Thromb Haemost. 2019;119(2):319-27.
142 Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-71.
143 Sharifi M, Bay C, Skrocki L, Lawson D, Mazdeh S. Role of IVC filters in endovenous therapy for deep venous thrombosis: the FILTER-PEVI (Filter Implantation to Lower Thromboembolic Risk in Percutaneous Endovenous Intervention) trial. Cardiovasc Intervent Radiol. 2012;35(6):1408-13.
144 Duffett L, Carrier M. Infenor vena cava filters. J Thromb Haemost. 2017;15(1):3-12.
145 PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005;112(3):416-22.
146 Mismetti P, Laporte S, Pellerin O, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism a randomized clinical trial. JAMA. 2015;313(16):1627-35.
147 Enden T, Haig Y, Klow NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012;379(9810):31-8.
148 Haig Y, Enden T, Grotta O, et al. Post-thrombotic syndrome after catheter-directed throm- bolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol. 2016;3(2):e64-71.
149 Enden T, Wik HS, Kvam AK, Haig Y, Klow NE, Sandset PM. Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the rando- mised, non-blinded, parallel-group CaVenT study. BMJ Open. 2013;3(8):e002984.
150 Enden T, Resch S, White C, Wik HS, Klow NE, Sandset PM. Cost- effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis. J Thromb Haemost. 2013;11(6):1032-42.
151 Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical catheter-directed thrombol- ysis for deep-vein thrombosis. N Engl J Med. 2017;377(23):2240-52.
152 Vedantham S, Salter A, Lancia S, Lewis L, Thukral S, Kahn SR. Clinical outcomes of a pharmacomechanical catheter-directed venous thrombolysis strategy that included rheolytic thrombectomy in a multicenter randomized trial. J Vasc Interv Radiol. 2021;32(9):1296-1309.e7.
153 Notten P, Ten Cate-Hoek AJ, Arnoldussen C, et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post- thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. Lancet Haematol. 2020;7(1):e40-9.
154 Comerota AJ, Kearon C, Gu CS, et al. Endovascular thrombus removal for acute ilio- femoral deep vein thrombosis. Circulation. 2019;139(9):1162-73.
155 Kearon C, Gu CS, Julian JA, et al. Pharmacomechanical catheter-directed thrombolysis in acute femoral-popliteal deep vein thrombosis: analysis from a stratified randomized trial. Thromb Haemost. 2019;119(4):633-44.
156 Broderick C, Watson L, Armon MP. Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb. Cochrane Database Syst Rev. 2021;1(1):CD002783. PMid:33464575.
157 McBane RD 2nd, Torres Roldan VD, Niven AS, et al. Anticoagulation in COVID-19: a systematic review, meta-analysis, and rapid guidance from Mayo Clinic. Mayo Clin Proc. 2020;95(11):2467-86.
158 Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine. 2020;29:100639.
159 Kunutsor SK, Laukkanen JA. Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and meta-analysis. Thromb Res. 2020;196:27-30.
160 Kollias A, Kyriakoulis KG, Lagou S, Kontopantelis E, Stergiou GS, Syrigos K. Venous thromboembolism in COVID-19: a systematic review and meta-analysis. Vasc Med. 2021;26(4):415-25.
161 Cook DJ, Crowther MA. Thromboprophylaxis in the intensive care unit: focus on medical–surgical patients. Crit Care Med. 2010;38(2, Suppl):S76-82.
162 Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med. 2004;164(9):963-8.
163 Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341(11):793-800.
164 Suh YJ, Hong H, Ohana M, et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology. 2021;298(2):E70-80.
165 Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2, Suppl):e351S-418S.
166 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
167 Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res. 2020;192:23-6.
168 Paliogiannis P, Mangoni AA, Dettori P, Nasrallah GK, Pintus G, Zinellu A. D-dimer concentrations and COVID-19 severity: a systematic review and meta-analysis. Front Public Health. 2020;8:432.
169 Zhang A, Leng Y, Zhang Y, et al. Meta-analysis of coagulation parameters associated with disease severity and poor prognosis of COVID-19. Int J Infect Dis. 2020;100:441-8.
170 Gaitini D. Current approaches and controversial issues in the diagnosis of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound. 2006;34(6):289-97.
171 Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-52.
172 Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic anticoagulation with heparin in critically Ill patients with Covid-19. N Engl J Med. 2021;385(9):777-89.
173 Lawler PR, Goligher EC, Berger JS, et al. Therapeutic anticoagulation with heparin in Noncritically Ill patients with Covid-19. N Engl J Med. 2021;385(9):790-802.
174 Sadeghipour P, Talasaz AH, Rashidi F, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the Intensive Care Unit: the INSPIRATION Randomized Clinical Trial. JAMA. 2021;325(16):1620-30.
175 Lemos ACB, Espírito Santo DA, Salvetti MC, et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID). Thromb Res. 2020;196:359-66.
176 Jiménez D, García-Sanchez A, Rali P, et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest. 2021;159(3):1182-96.
177 Giannis D, Allen SL, Tsang J, et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood. 2021;137(20):2838-47.
178 Ramacciotti E, Barile Agati L, Calderaro D, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;399(10319):50-9.
Submetido em:
03/07/2023
Aceito em:
01/12/2023
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email